Skip to main content
Top
Published in: Current Hepatology Reports 1/2020

Open Access 01-03-2020 | Compartment Syndrome | Portal Hypertension (J Gonzalez-Abraldes and E Tsochatzis, Section Editors)

The Role of Vascular Injury and Congestion in the Pathogenesis of Cirrhosis: the Congestive Escalator and the Parenchymal Extinction Sequence

Author: Ian R. Wanless

Published in: Current Hepatology Reports | Issue 1/2020

Login to get access

Abstract

Purpose of Review

Current research into the pathogenesis of cirrhosis is largely dominated by investigations of hepatocellular injury and fibrogenesis, mostly in short-term experimental models. Cirrhosis in the human evolves for decades with histologic features that are very different from the models studied, dominated by hepatic vein obstruction and congestion. This is a clue that the mechanisms operating in the human are different from those in most animal models.

Recent Findings

This paper presents an updated “vascular hypothesis” with previously unpublished observations that provide a more complete understanding of the pathogenesis of chronic liver disease in the human: (1) a definition of parenchymal extinction emphasizing the importance of sinusoidal destruction, (2) analysis of the temporal evolution of parenchymal extinction lesions, (3) new data to quantify hepatic vein obstruction, (4) a “congestive escalator” hypothesis to explain how vascular obstruction occurs, beginning with sinusoidal endothelial cell injury, fluid translocation, and vascular compression by mechanics known as “compartment syndrome,” (5) a “nested cone model” of hepatic vein anatomy that predisposes to compartment syndrome in the human, and (6) a proposal for the mechanism of collagen formation in response to congestion (“congestive fibrosis”).

Summary

The guiding principle in this model is that flow has to be vented to keep pressure gradients within the physiological range. Vascular obstruction causes tissue congestion which induces further vascular obstruction that drives a congestive escalator leading to progressive parenchymal extinction. This model may be applicable to all types of cirrhosis found in the human.
Appendix
Available only for authorised users
Literature
1.
go back to reference Garcia-Pagan JC, Gracia-Sancho J, Bosch J. Functional aspects on the pathophysiology of portal hypertension in cirrhosis. J Hepatol. 2012;57(2):458–61.CrossRef Garcia-Pagan JC, Gracia-Sancho J, Bosch J. Functional aspects on the pathophysiology of portal hypertension in cirrhosis. J Hepatol. 2012;57(2):458–61.CrossRef
2.
go back to reference Peverill W, Powell LW, Skoien R. Evolving concepts in the pathogenesis of NASH: beyond steatosis and inflammation. Int J Mol Sci. 2014;15(5):8591–638.CrossRef Peverill W, Powell LW, Skoien R. Evolving concepts in the pathogenesis of NASH: beyond steatosis and inflammation. Int J Mol Sci. 2014;15(5):8591–638.CrossRef
3.
go back to reference Trautwein C, Friedman SL, Schuppan D, Pinzani M. Hepatic fibrosis: concept to treatment. J Hepatol. 2015;62(1 Suppl):S15–24.CrossRef Trautwein C, Friedman SL, Schuppan D, Pinzani M. Hepatic fibrosis: concept to treatment. J Hepatol. 2015;62(1 Suppl):S15–24.CrossRef
4.
go back to reference Seki E, Brenner DA. Recent advancement of molecular mechanisms of liver fibrosis. J Hepatobiliary Pancreat Sci. 2015;22(7):512–8.CrossRef Seki E, Brenner DA. Recent advancement of molecular mechanisms of liver fibrosis. J Hepatobiliary Pancreat Sci. 2015;22(7):512–8.CrossRef
5.
go back to reference Karin D, Koyama Y, Brenner D, Kisseleva T. The characteristics of activated portal fibroblasts/myofibroblasts in liver fibrosis. Differentiation. 2016;92(3):84–92.CrossRef Karin D, Koyama Y, Brenner D, Kisseleva T. The characteristics of activated portal fibroblasts/myofibroblasts in liver fibrosis. Differentiation. 2016;92(3):84–92.CrossRef
6.
go back to reference Koyama Y, Brenner DA. Liver inflammation and fibrosis. J Clin Invest. 2017;127(1):55–64.CrossRef Koyama Y, Brenner DA. Liver inflammation and fibrosis. J Clin Invest. 2017;127(1):55–64.CrossRef
7.
go back to reference Yang L, Kwon J, Popov Y, Gajdos GB, Ordog T, Brekken RA, et al. Vascular endothelial growth factor promotes fibrosis resolution and repair in mice. Gastroenterology. 2014;146(5):1339–50 e1.CrossRef Yang L, Kwon J, Popov Y, Gajdos GB, Ordog T, Brekken RA, et al. Vascular endothelial growth factor promotes fibrosis resolution and repair in mice. Gastroenterology. 2014;146(5):1339–50 e1.CrossRef
8.
go back to reference •• Villa E, Camma C, Marietta M, Luongo M, Critelli R, Colopi S, et al. Enoxaparin prevents portal vein thrombosis and liver decompensation in patients with advanced cirrhosis. Gastroenterology. 2012;143(5):1253–1260 e4. Clinical trial indicating that modulation of coagulation pathways may influence the natural history of cirrhosis. •• Villa E, Camma C, Marietta M, Luongo M, Critelli R, Colopi S, et al. Enoxaparin prevents portal vein thrombosis and liver decompensation in patients with advanced cirrhosis. Gastroenterology. 2012;143(5):1253–1260 e4. Clinical trial indicating that modulation of coagulation pathways may influence the natural history of cirrhosis.
9.
go back to reference Schepis F, Villa E. Thrombophilic genetic risk factors for liver fibrosis: to screen or not to screen? J Hepatol. 2015;63(6):1311–3.CrossRef Schepis F, Villa E. Thrombophilic genetic risk factors for liver fibrosis: to screen or not to screen? J Hepatol. 2015;63(6):1311–3.CrossRef
10.
go back to reference •• Tripathi DM, Vilaseca M, Lafoz E, Garcia-Caldero H, Viegas Haute G, Fernandez-Iglesias A, et al. Simvastatin prevents progression of acute on chronic liver failure in rats with cirrhosis and portal hypertension. Gastroenterology. 2018;155(5):1564–77. Animal model indicating that simvastatin may influence the natural history of cirrhosis. •• Tripathi DM, Vilaseca M, Lafoz E, Garcia-Caldero H, Viegas Haute G, Fernandez-Iglesias A, et al. Simvastatin prevents progression of acute on chronic liver failure in rats with cirrhosis and portal hypertension. Gastroenterology. 2018;155(5):1564–77. Animal model indicating that simvastatin may influence the natural history of cirrhosis.
11.
go back to reference Meireles CZ, Pasarin M, Lozano JJ, Garcia-Caldero H, Gracia-Sancho J, Garcia-Pagan JC, et al. Simvastatin attenuates liver injury in rodents with biliary cirrhosis submitted to hemorrhage/resuscitation. Shock. 2017;47(3):370–7.CrossRef Meireles CZ, Pasarin M, Lozano JJ, Garcia-Caldero H, Gracia-Sancho J, Garcia-Pagan JC, et al. Simvastatin attenuates liver injury in rodents with biliary cirrhosis submitted to hemorrhage/resuscitation. Shock. 2017;47(3):370–7.CrossRef
12.
go back to reference Turco L, Villanueva C, La Mura V, Garcia-Pagan JC, Reiberger T, Genesca J, et al. Lowering portal pressure improves outcomes of patients with cirrhosis, with or without ascites: a meta-analysis. Clin Gastroenterol Hepatol. 2019. Turco L, Villanueva C, La Mura V, Garcia-Pagan JC, Reiberger T, Genesca J, et al. Lowering portal pressure improves outcomes of patients with cirrhosis, with or without ascites: a meta-analysis. Clin Gastroenterol Hepatol. 2019.
13.
go back to reference Wanless IR. An hypothesis for the pathogenesis of cirrhosis based on vascular pathology of liver in pre-cirrhotic states. Mod Pathol. 1994;7:136A. Wanless IR. An hypothesis for the pathogenesis of cirrhosis based on vascular pathology of liver in pre-cirrhotic states. Mod Pathol. 1994;7:136A.
14.
go back to reference •• Wanless IR, Wong F, Blendis LM, Greig P, Heathcote EJ, Levy G. Hepatic and portal vein thrombosis in cirrhosis: possible role in development of parenchymal extinction and portal hypertension. Hepatology. 1995;21(5):1238–47. First hypothesis that vascular obstruction, possibly related to thrombosis, has a role in tissue loss and fibrosis found in human chronic liver disease. •• Wanless IR, Wong F, Blendis LM, Greig P, Heathcote EJ, Levy G. Hepatic and portal vein thrombosis in cirrhosis: possible role in development of parenchymal extinction and portal hypertension. Hepatology. 1995;21(5):1238–47. First hypothesis that vascular obstruction, possibly related to thrombosis, has a role in tissue loss and fibrosis found in human chronic liver disease.
15.
go back to reference Wanless IR. Thrombosis and phlebitis in the pathogenesis of portal hypertension and cirrhosis: the 2-hit hypothesis for the pathogenesis of chronic liver disease. In: Arroyo V, Bosch J, Bruguera M, Rodes J, editors. Therapy in liver diseases. 3rd ed. Barcelona: Masson; 1997. p. 47–50. Wanless IR. Thrombosis and phlebitis in the pathogenesis of portal hypertension and cirrhosis: the 2-hit hypothesis for the pathogenesis of chronic liver disease. In: Arroyo V, Bosch J, Bruguera M, Rodes J, editors. Therapy in liver diseases. 3rd ed. Barcelona: Masson; 1997. p. 47–50.
16.
go back to reference Wanless IR, Huang W-Y. Vascular disorders. In: Burt AD, Portmann BC, Ferrell L, editors. MacSween’s pathology of the liver. 6th ed. Edinburgh: Churchill-Livingstone-Elsevier; 2012. p. 601–43.CrossRef Wanless IR, Huang W-Y. Vascular disorders. In: Burt AD, Portmann BC, Ferrell L, editors. MacSween’s pathology of the liver. 6th ed. Edinburgh: Churchill-Livingstone-Elsevier; 2012. p. 601–43.CrossRef
17.
go back to reference Edwards L, Wanless IR. Mechanisms of liver involvement in systemic disease. Best Pract Res Clin Gastroenterol. 2013;27(4):471–83.CrossRef Edwards L, Wanless IR. Mechanisms of liver involvement in systemic disease. Best Pract Res Clin Gastroenterol. 2013;27(4):471–83.CrossRef
18.
go back to reference • Wanless IR. Physioanatomic considerations. In: Schiff ER, Maddrey WC, Reddy KR, editors. Schiff’s diseases of the liver. 12th ed. Oxford: John Wiley and Sons; 2018. p. 73–102. Recent summary of the role of hepatic vascular disease in the pathogenesis and natural history of chronic liver disease. • Wanless IR. Physioanatomic considerations. In: Schiff ER, Maddrey WC, Reddy KR, editors. Schiff’s diseases of the liver. 12th ed. Oxford: John Wiley and Sons; 2018. p. 73–102. Recent summary of the role of hepatic vascular disease in the pathogenesis and natural history of chronic liver disease.
19.
go back to reference Wanless I. Pathology of Budd-Chiari syndrome and Hepatic vein obstruction. In: Qi X, editor. Budd Chiari Syndrome. Berlin: Springer; 2019. p. in press. Springer Nature Singapore; 2020, 27-38. Wanless I. Pathology of Budd-Chiari syndrome and Hepatic vein obstruction. In: Qi X, editor. Budd Chiari Syndrome. Berlin: Springer; 2019. p. in press. Springer Nature Singapore; 2020, 27-38.
20.
go back to reference Stueck AE, Wanless IR. Hepatocyte buds derived from progenitor cells repopulate regions of parenchymal extinction in human cirrhosis. Hepatology. 2015;61(5):1696–707.CrossRef Stueck AE, Wanless IR. Hepatocyte buds derived from progenitor cells repopulate regions of parenchymal extinction in human cirrhosis. Hepatology. 2015;61(5):1696–707.CrossRef
21.
go back to reference • Goodman ZD, Ishak KG. Occlusive venous lesions in alcoholic liver disease: a study of 200 cases. Gastroenterology. 1982;83:786–96. Early report of hepatic vascular disease in patients with cirrhosis. • Goodman ZD, Ishak KG. Occlusive venous lesions in alcoholic liver disease: a study of 200 cases. Gastroenterology. 1982;83:786–96. Early report of hepatic vascular disease in patients with cirrhosis.
22.
go back to reference Nakanuma Y, Ohta G, Doishita K. Quantitation and serial section observations of focal veno-occlusive lesions of hepatic veins in liver cirrhosis. Virchows Arch (Pathol Anat). 1985;405:429–38. Nakanuma Y, Ohta G, Doishita K. Quantitation and serial section observations of focal veno-occlusive lesions of hepatic veins in liver cirrhosis. Virchows Arch (Pathol Anat). 1985;405:429–38.
23.
go back to reference Burt AD, MacSween RNM. Hepatic vein lesions in alcoholic liver disease: retrospective biopsy and necropsy study. J Clin Pathol. 1986;39(1):63-7. Burt AD, MacSween RNM. Hepatic vein lesions in alcoholic liver disease: retrospective biopsy and necropsy study. J Clin Pathol. 1986;39(1):63-7.
24.
go back to reference Wanless IR, Nakashima E, Sherman M. Regression of human cirrhosis: morphologic features and the genesis of incomplete septal cirrhosis. Arch Pathol Lab Med. 2000;124:1599-607. Wanless IR, Nakashima E, Sherman M. Regression of human cirrhosis: morphologic features and the genesis of incomplete septal cirrhosis. Arch Pathol Lab Med. 2000;124:1599-607.
25.
go back to reference • Wanless IR, Shiota K. The pathogenesis of nonalcoholic steatohepatitis and other fatty liver diseases: a four-step model including the role of lipid release and hepatic venular obstruction in the progression to cirrhosis. Semin Liver Dis. 2004;24(1):99–106. This paper documents hepatic vein obstruction in early NASH. A hypothesis is presented that integrates the roles of elevated insulin levels, lipid toxicity, and vascular obstruction in the pathogenesis of NASH. • Wanless IR, Shiota K. The pathogenesis of nonalcoholic steatohepatitis and other fatty liver diseases: a four-step model including the role of lipid release and hepatic venular obstruction in the progression to cirrhosis. Semin Liver Dis. 2004;24(1):99–106. This paper documents hepatic vein obstruction in early NASH. A hypothesis is presented that integrates the roles of elevated insulin levels, lipid toxicity, and vascular obstruction in the pathogenesis of NASH.
26.
go back to reference Guido M, Sarcognato S, Russo FP, Cardin R, Piciocchi M, Colloredo G, et al. Focus on histological abnormalities of intrahepatic vasculature in chronic viral hepatitis. Liver Int. 2018;38(10):1770-6. Guido M, Sarcognato S, Russo FP, Cardin R, Piciocchi M, Colloredo G, et al. Focus on histological abnormalities of intrahepatic vasculature in chronic viral hepatitis. Liver Int. 2018;38(10):1770-6.
27.
go back to reference Malkan G, Humar A, Lilly L, Greig PD, Grant D, Wanless IW, et al. Natural history of recurrent hepatitis C after liver transplantation. Transplant Proc. 2001;33(1-2):1468. Malkan G, Humar A, Lilly L, Greig PD, Grant D, Wanless IW, et al. Natural history of recurrent hepatitis C after liver transplantation. Transplant Proc. 2001;33(1-2):1468.
28.
go back to reference Wanless IR, Kutami R, Shiota K. Pathology of recurrent hepatitis C after liver transplantation: a model system to study the histogenesis of cirrhosis. Hepatology. 2001;34(4 part 2):218A. Wanless IR, Kutami R, Shiota K. Pathology of recurrent hepatitis C after liver transplantation: a model system to study the histogenesis of cirrhosis. Hepatology. 2001;34(4 part 2):218A.
29.
go back to reference Krasinskas AM, Goldsmith JD, Burke A, Furth EE. Abnormal intrahepatic portal vasculature in native and allograft liver biopsies: a comparative analysis. Am J Surg Pathol. 2005;29(10):1382-8. Krasinskas AM, Goldsmith JD, Burke A, Furth EE. Abnormal intrahepatic portal vasculature in native and allograft liver biopsies: a comparative analysis. Am J Surg Pathol. 2005;29(10):1382-8.
30.
go back to reference Arnason T, Fleming K, Wanless IR. Peritumoural hyperplasia of the liver: a response to portal vein invasion by hypervascular neoplasms. Histopathology. 2013;62:458–64. Arnason T, Fleming K, Wanless IR. Peritumoural hyperplasia of the liver: a response to portal vein invasion by hypervascular neoplasms. Histopathology. 2013;62:458–64.
31.
go back to reference Ward NL, Haninec AL, Van Slyke P, Sled JG, Sturk C, Henkelman RM, et al. Angiopoietin-1 causes reversible degradation of the portal microcirculation in mice: implications for treatment of liver disease. Am J Pathol. 2004;165(3):889-99. Ward NL, Haninec AL, Van Slyke P, Sled JG, Sturk C, Henkelman RM, et al. Angiopoietin-1 causes reversible degradation of the portal microcirculation in mice: implications for treatment of liver disease. Am J Pathol. 2004;165(3):889-99.
32.
go back to reference Nakashima E, Kage M, Wanless IR. Idiopathic portal hypertension: histologic evidence that some cases may be regressed cirrhosis with portal vein thrombosis. Hepatology 1999;30:218A. Nakashima E, Kage M, Wanless IR. Idiopathic portal hypertension: histologic evidence that some cases may be regressed cirrhosis with portal vein thrombosis. Hepatology 1999;30:218A.
33.
go back to reference Wanless IR. The mechanism of irreversibility of late stage cirrhosis. J Hepatology. 2018;68(suppl 1):S692. Wanless IR. The mechanism of irreversibility of late stage cirrhosis. J Hepatology. 2018;68(suppl 1):S692.
34.
go back to reference Hano H, Takasaki S, Endo Y, Harada T, Komine K, Koike Y. Histological reassessment of the role of bridging fibrosis in the angioarchitectural features associated with lobular distortion of the liver in chronic viral hepatitis. Hepatol Res. 2016;46(3):E70-8. Hano H, Takasaki S, Endo Y, Harada T, Komine K, Koike Y. Histological reassessment of the role of bridging fibrosis in the angioarchitectural features associated with lobular distortion of the liver in chronic viral hepatitis. Hepatol Res. 2016;46(3):E70-8.
35.
go back to reference Mall FP. A study of the structural unit of the liver. Am J Anat. 1906;5:18-308. Mall FP. A study of the structural unit of the liver. Am J Anat. 1906;5:18-308.
36.
go back to reference Wanless IR. Arterialization of the liver causes baro-injury in cirrhosis and focal nodular hyperplasia (FNH). Hepatology. 1999;30:571A. Wanless IR. Arterialization of the liver causes baro-injury in cirrhosis and focal nodular hyperplasia (FNH). Hepatology. 1999;30:571A.
37.
go back to reference Wanless IR, Bernier V. Fibrous thickening of the splenic capsule. A response to chronic splenic congestion. Arch Pathol Lab Med. 1983;107(11):595-9. Wanless IR, Bernier V. Fibrous thickening of the splenic capsule. A response to chronic splenic congestion. Arch Pathol Lab Med. 1983;107(11):595-9.
38.
go back to reference Wanless IR, Liu JJ, Butany J. Role of thrombosis in the pathogenesis of congestive hepatic fibrosis (cardiac cirrhosis). Hepatology. 1995;21(5):1232-7. Wanless IR, Liu JJ, Butany J. Role of thrombosis in the pathogenesis of congestive hepatic fibrosis (cardiac cirrhosis). Hepatology. 1995;21(5):1232-7.
39.
go back to reference Mueller S. Does pressure cause liver cirrhosis? The sinusoidal pressure hypothesis. . World J Gastroenterol 2016;22:10482-501. Mueller S. Does pressure cause liver cirrhosis? The sinusoidal pressure hypothesis. . World J Gastroenterol 2016;22:10482-501.
40.
go back to reference Frickhofen N, Wiesneth M, Jainta C, Hertenstein B, Heymer B, Bianchi L, et al. Hepatitis C virus infection is a risk factor for liver failure from veno-occlusive disease after bone marrow transplantation. Blood. 1994;83(7):1998-2004. Frickhofen N, Wiesneth M, Jainta C, Hertenstein B, Heymer B, Bianchi L, et al. Hepatitis C virus infection is a risk factor for liver failure from veno-occlusive disease after bone marrow transplantation. Blood. 1994;83(7):1998-2004.
41.
go back to reference Sabbagh C, Cosse C, Chauffert B, Nguyen-Khac E, Joly JP, Yzet T, et al. Management of colon cancer in patients with cirrhosis: a review. Surg Oncol. 2015;24(3):187-93. Sabbagh C, Cosse C, Chauffert B, Nguyen-Khac E, Joly JP, Yzet T, et al. Management of colon cancer in patients with cirrhosis: a review. Surg Oncol. 2015;24(3):187-93.
42.
go back to reference Marrone G, Maeso-Diaz R, Garcia-Cardena G, Abraldes JG, Garcia-Pagan JC, Bosch J, et al. KLF2 exerts antifibrotic and vasoprotective effects in cirrhotic rat livers: behind the molecular mechanisms of statins. Gut. 2015;64(9):1434-43. Marrone G, Maeso-Diaz R, Garcia-Cardena G, Abraldes JG, Garcia-Pagan JC, Bosch J, et al. KLF2 exerts antifibrotic and vasoprotective effects in cirrhotic rat livers: behind the molecular mechanisms of statins. Gut. 2015;64(9):1434-43.
43.
go back to reference • Abraldes JG, Villanueva C, Aracil C, Turnes J, Hernandez-Guerra M, Genesca J, et al. Addition of simvastatin to standard therapy for the prevention of variceal rebleeding does not reduce rebleeding but increases survival in patients with cirrhosis. Gastroenterology. 2016;150(5):1160-70 e3. Clinical trial indicating that simvastatin may influence the natural history of cirrhosis. • Abraldes JG, Villanueva C, Aracil C, Turnes J, Hernandez-Guerra M, Genesca J, et al. Addition of simvastatin to standard therapy for the prevention of variceal rebleeding does not reduce rebleeding but increases survival in patients with cirrhosis. Gastroenterology. 2016;150(5):1160-70 e3. Clinical trial indicating that simvastatin may influence the natural history of cirrhosis.
Metadata
Title
The Role of Vascular Injury and Congestion in the Pathogenesis of Cirrhosis: the Congestive Escalator and the Parenchymal Extinction Sequence
Author
Ian R. Wanless
Publication date
01-03-2020
Publisher
Springer US
Published in
Current Hepatology Reports / Issue 1/2020
Electronic ISSN: 2195-9595
DOI
https://doi.org/10.1007/s11901-020-00508-y

Other articles of this Issue 1/2020

Current Hepatology Reports 1/2020 Go to the issue

Nutrition in Patients with Chronic Liver Disease (E Tapper, Section Editor)

What Diet Should I Recommend My Patient with Hepatic Encephalopathy?

Portal Hypertension and Liver Transplantation (R Reddy, Section Editor)

Recurrent Disease After Liver Transplantation

Nutrition in Patients with Chronic Liver Disease (E Tapper, Section Editor)

Nutrition Management in the Critically Ill Patient with Cirrhosis

Nutrition in Patients with Chronic Liver Disease (E Tapper, Section Editor)

Food as Therapy for Frailty

Nutrition in Patients with Chronic Liver Disease (E Tapper, Section Editor)

Nutrition in Cholestatic Liver Disease